Treatment of Turner's syndrome with recombinant human growth hormone (somatrem)

B. Lippe, Ronald (Ron) Rosenfeld, R. L. Hintz, A. J. Johanson, J. Frane, B. Sherman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This report extends to 3 years the prospective study of the effects of somatrem alone or in combination with oxandrolone on growth in Turner's syndrome. Sixty-seven patients completed the 1-year study period during which all treatment groups had statistically increased height velocities as compared to the control group. Oral glucose tolerance and insulin response remained unchanged after 1 year of somatrem treatment. The group receiving oxandrolone experienced an increase in integrated glucose response and the group receiving combined therapy an increase in both integrated glucose and insulin responses. During the second and third years the somatrem group remained on the same dose and treatment schedule and grew at mean velocities of 5.4 ± 1.1 and 4.6 ± 1.4 cm/year. The dose of oxandrolone was reduced by 50% during the second and third years for the combination group. The somatrem dose remained unchanged. This group had height velocities of 7.4 ± 1.4 cm and 6.1 ± 1.5 cm/year. The control group and the group treated with oxandrolone alone were converted to combined therapy at the lowered oxandrolone dose. Their growth rates during the second year were 8.3 ± 1.2 and 7.1 ± 1.6 cm/year, respectively. Using bone age determinations and the methods of Bayley and Pinneau, all groups currently show predicted increases in final adult height.

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
JournalActa Paediatrica Scandinavica
Volume77
Issue numberSUPPL. 343
StatePublished - 1988
Externally publishedYes

Fingerprint

Oxandrolone
Turner Syndrome
Human Growth Hormone
Growth Hormone
Insulin
Therapeutics
Glucose
Control Groups
Glucose Tolerance Test
Growth
Appointments and Schedules
somatrem
Prospective Studies
Bone and Bones

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Lippe, B., Rosenfeld, R. R., Hintz, R. L., Johanson, A. J., Frane, J., & Sherman, B. (1988). Treatment of Turner's syndrome with recombinant human growth hormone (somatrem). Acta Paediatrica Scandinavica, 77(SUPPL. 343), 47-52.

Treatment of Turner's syndrome with recombinant human growth hormone (somatrem). / Lippe, B.; Rosenfeld, Ronald (Ron); Hintz, R. L.; Johanson, A. J.; Frane, J.; Sherman, B.

In: Acta Paediatrica Scandinavica, Vol. 77, No. SUPPL. 343, 1988, p. 47-52.

Research output: Contribution to journalArticle

Lippe, B, Rosenfeld, RR, Hintz, RL, Johanson, AJ, Frane, J & Sherman, B 1988, 'Treatment of Turner's syndrome with recombinant human growth hormone (somatrem)', Acta Paediatrica Scandinavica, vol. 77, no. SUPPL. 343, pp. 47-52.
Lippe B, Rosenfeld RR, Hintz RL, Johanson AJ, Frane J, Sherman B. Treatment of Turner's syndrome with recombinant human growth hormone (somatrem). Acta Paediatrica Scandinavica. 1988;77(SUPPL. 343):47-52.
Lippe, B. ; Rosenfeld, Ronald (Ron) ; Hintz, R. L. ; Johanson, A. J. ; Frane, J. ; Sherman, B. / Treatment of Turner's syndrome with recombinant human growth hormone (somatrem). In: Acta Paediatrica Scandinavica. 1988 ; Vol. 77, No. SUPPL. 343. pp. 47-52.
@article{4368acb56e1446fc9df11b2161fdbaa1,
title = "Treatment of Turner's syndrome with recombinant human growth hormone (somatrem)",
abstract = "This report extends to 3 years the prospective study of the effects of somatrem alone or in combination with oxandrolone on growth in Turner's syndrome. Sixty-seven patients completed the 1-year study period during which all treatment groups had statistically increased height velocities as compared to the control group. Oral glucose tolerance and insulin response remained unchanged after 1 year of somatrem treatment. The group receiving oxandrolone experienced an increase in integrated glucose response and the group receiving combined therapy an increase in both integrated glucose and insulin responses. During the second and third years the somatrem group remained on the same dose and treatment schedule and grew at mean velocities of 5.4 ± 1.1 and 4.6 ± 1.4 cm/year. The dose of oxandrolone was reduced by 50{\%} during the second and third years for the combination group. The somatrem dose remained unchanged. This group had height velocities of 7.4 ± 1.4 cm and 6.1 ± 1.5 cm/year. The control group and the group treated with oxandrolone alone were converted to combined therapy at the lowered oxandrolone dose. Their growth rates during the second year were 8.3 ± 1.2 and 7.1 ± 1.6 cm/year, respectively. Using bone age determinations and the methods of Bayley and Pinneau, all groups currently show predicted increases in final adult height.",
author = "B. Lippe and Rosenfeld, {Ronald (Ron)} and Hintz, {R. L.} and Johanson, {A. J.} and J. Frane and B. Sherman",
year = "1988",
language = "English (US)",
volume = "77",
pages = "47--52",
journal = "Acta Paediatrica, International Journal of Paediatrics",
issn = "0803-5253",
publisher = "Wiley-Blackwell",
number = "SUPPL. 343",

}

TY - JOUR

T1 - Treatment of Turner's syndrome with recombinant human growth hormone (somatrem)

AU - Lippe, B.

AU - Rosenfeld, Ronald (Ron)

AU - Hintz, R. L.

AU - Johanson, A. J.

AU - Frane, J.

AU - Sherman, B.

PY - 1988

Y1 - 1988

N2 - This report extends to 3 years the prospective study of the effects of somatrem alone or in combination with oxandrolone on growth in Turner's syndrome. Sixty-seven patients completed the 1-year study period during which all treatment groups had statistically increased height velocities as compared to the control group. Oral glucose tolerance and insulin response remained unchanged after 1 year of somatrem treatment. The group receiving oxandrolone experienced an increase in integrated glucose response and the group receiving combined therapy an increase in both integrated glucose and insulin responses. During the second and third years the somatrem group remained on the same dose and treatment schedule and grew at mean velocities of 5.4 ± 1.1 and 4.6 ± 1.4 cm/year. The dose of oxandrolone was reduced by 50% during the second and third years for the combination group. The somatrem dose remained unchanged. This group had height velocities of 7.4 ± 1.4 cm and 6.1 ± 1.5 cm/year. The control group and the group treated with oxandrolone alone were converted to combined therapy at the lowered oxandrolone dose. Their growth rates during the second year were 8.3 ± 1.2 and 7.1 ± 1.6 cm/year, respectively. Using bone age determinations and the methods of Bayley and Pinneau, all groups currently show predicted increases in final adult height.

AB - This report extends to 3 years the prospective study of the effects of somatrem alone or in combination with oxandrolone on growth in Turner's syndrome. Sixty-seven patients completed the 1-year study period during which all treatment groups had statistically increased height velocities as compared to the control group. Oral glucose tolerance and insulin response remained unchanged after 1 year of somatrem treatment. The group receiving oxandrolone experienced an increase in integrated glucose response and the group receiving combined therapy an increase in both integrated glucose and insulin responses. During the second and third years the somatrem group remained on the same dose and treatment schedule and grew at mean velocities of 5.4 ± 1.1 and 4.6 ± 1.4 cm/year. The dose of oxandrolone was reduced by 50% during the second and third years for the combination group. The somatrem dose remained unchanged. This group had height velocities of 7.4 ± 1.4 cm and 6.1 ± 1.5 cm/year. The control group and the group treated with oxandrolone alone were converted to combined therapy at the lowered oxandrolone dose. Their growth rates during the second year were 8.3 ± 1.2 and 7.1 ± 1.6 cm/year, respectively. Using bone age determinations and the methods of Bayley and Pinneau, all groups currently show predicted increases in final adult height.

UR - http://www.scopus.com/inward/record.url?scp=0023767210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023767210&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 47

EP - 52

JO - Acta Paediatrica, International Journal of Paediatrics

JF - Acta Paediatrica, International Journal of Paediatrics

SN - 0803-5253

IS - SUPPL. 343

ER -